Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Affitech and Omeros have signed an agreement for the discovery and development of fully human antibodies for Omeros's MASP-2 program.
Subscribe to our email newsletter
MASP-2, or mannan-binding lectin-associated serine protease-2, mediates activation of the complement system via the lectin pathway and is linked to multiple potential indications across a wide range of inflammatory diseases including macular degeneration, rheumatoid arthritis, transplant rejection and cardiovascular and renal ischemia-reperfusion injury.
Under this collaboration, Omeros, based on its exclusive intellectual property position, will continue to advance the development of its MASP-2 program. Affitech will apply its expansive human antibody libraries and proprietary antibody discovery and screening technologies, including its AffiScreen platform and engineering methods, to generate fully human MASP-2 antibodies for Omeros.
Financial terms include a technology access fee, a series of milestone payments, and royalties on net sales, payable by Omeros.
Gregory Demopulos, chairman and CEO of Omeros, said: “This agreement marks an important milestone in our MASP-2 program, and ensures that Omeros can access high-affinity, fully human antibodies against MASP-2. We are impressed by Affitech’s technology, track record and personnel, and look forward to our collaboration.”